# Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer

> **NCT00824161** · PHASE2 · TERMINATED · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 28 (actual)

## Conditions studied

- Advanced Colorectal Cancer

## Interventions

- **DRUG:** TAS-109

## Key facts

- **NCT ID:** NCT00824161
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2009-11
- **Final completion:** 2010-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2012-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00824161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00824161, "Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00824161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*